Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 1/20 | 0.62 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | MPL | P40238 | 9/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4878410 | 0.83 | AURKA (0.60) | AURKAMPLNPC1RAB9AMKNK1 | |
| SCHEMBL13434904 | 0.82 | MPL (0.54) | MPL | |
| SCHEMBL13434906 | 0.81 | ROCK1 (0.61) | ROCK1AURKAMPLMKNK1 | |
| SCHEMBL23999861 | 0.80 | KMT2A (0.57) | ROCK1MEN1KMT2AKDM4EHPGD | |
| SCHEMBL6093171 | 0.80 | NPC1 (0.68) | ROCK1AURKAMEN1KMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL4868695 | 0.80 | MPL (0.49) | MPLMKNK1 | |
| SCHEMBL647152 | 0.79 | ROCK1 (0.58) | ROCK1AURKAMEN1KMT2AKDM4E | |
| SCHEMBL13434903 | 0.79 | MPL (0.48) | MPLMKNK1 | |
| SCHEMBL26436181 | 0.79 | MAPK1 (0.53) | ROCK1MEN1KMT2AKDM4EHPGD | |
| SCHEMBL12484000 | 0.78 | MEN1 (0.49) | MEN1KMT2AKDM4EMPLMKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633201-B2 | Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-21 | — | — | US | disclosed |
| US-20100056548-A1 | THIENOPYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2010-03-04 | — | — | US | disclosed |
| US-20080076771-A1 | Thrombopoietin Receptor Agonists | REITER LAWRENCE A | 2008-03-27 | — | — | US | disclosed |
| EP-1794156-A2 | TROMBOPOIETIN RECEPTOR AGONISTS | Pfizer Products Incorporated (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006033005-A2 | THROMBOPOIETIN RECEPTOR AGONISTS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056548-A1 | THIENOPYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | CMPK1, DTYMK, NEK9 | ROCK1 2868/4885AURKA 341/4885MEN1 917/4885 |
| US-20080076771-A1 | Thrombopoietin Receptor Agonists | MPL, THPO, TBXA2R | ROCK1 2928/4885AURKA 4299/4885MEN1 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.